Japan-based Takeda Pharmaceutical said it has made an equity investment in San Diego-based Fate Therapeutics, the developer of stem cell technology. The amount wasn’t disclosed, but the announcement comes a few weeks after Fate disclosed in regulatory filings that it has increased the size of its current equity financing to $36 million, and pulled in another $1 million in debt financing. Takeda Ventures joins a syndicate of investors behind Fate, which includes Arch Venture Partners, OVP Venture Partners, Venrock, Polaris Venture Partners, Astellas Venture Management, Genzyme Ventures, and a third unnamed corporate venture investment group.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
